Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma

doi:10.1007/s00280-017-3507-2

	Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma
	Wang, Jingnan 1,2; Zhang, Zhirong1,2 ; Che, Yun 1,2; Yuan, Zuyang 1,2; Lu, Zhiliang 1,2; Li, Yuan 1,2; Wan, Jun 3; Sun, Handong3 ; Chen, Zhaoli 1,2; Pu, Jianxin3 ; He, Jie 1,2
	2018-03-01
发表期刊	CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN	0344-5704
卷号	81 期号:3 页码:469-481
摘要	Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive squamous cell carcinomas and is generally resistant to chemotherapy. In the present study, the cytotoxic activity of Rabdocoestin B (Rabd-B) against ESCC and the underlying mechanisms were investigated.
关键词	Rabdocoestin b G2/m Phase Arrest Apoptosis Cytotoxicity Esophageal Squamous Cell Carcinoma
DOI	10.1007/s00280-017-3507-2
语种	英语
WOS记录号	WOS:000426060100005
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/60543
专题	植物化学与西部植物资源持续利用国家重点实验室
作者单位	1.Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Thorac Surg, Beijing 100021, Peoples R China 2.Peking Union Med Coll, Beijing 100021, Peoples R China 3.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China
推荐引用方式 GB/T 7714	Wang, Jingnan,Zhang, Zhirong,Che, Yun,et al. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY,2018,81(3):469-481.
APA	Wang, Jingnan.,Zhang, Zhirong.,Che, Yun.,Yuan, Zuyang.,Lu, Zhiliang.,...&He, Jie.(2018).Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma.CANCER CHEMOTHERAPY AND PHARMACOLOGY,81(3),469-481.
MLA	Wang, Jingnan,et al."Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma".CANCER CHEMOTHERAPY AND PHARMACOLOGY 81.3(2018):469-481.